Lifitegrast (sodium salt)

Lifitegrast is an inhibitor of the protein-protein interaction between lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1). It binds to LFA-1 and blocks the adhesion of Jurkat T cells or HuT 78 cells to ICAM-1 (IC50s = 2.98 and 9 nM, respectively) and inhibits the secretion of various cytokines, including IFN-gamma, TNF-alpha, IL-1beta, and IL-6, from these cells. Lifitegrast increases tear production in dogs with idiopathic keratoconjunctivitis sicca. Topical application of lifitegrast inhibits LFA-1-dependent neutrophil recruitment to the eye in mouse models of contact lens-associated corneal inflammation induced by corneal abrasion and tobramycin-killed bacteria. Formulations containing lifitegrast have been used in the treatment of dry eye disease.Formal Name: N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-L-phenylalanine, monosodium salt. CAS Number: 1119276-80-0. Synonyms: SAR 1118-023. Molecular Formula: C29H23Cl2N2O7S . Na. Formula Weight: 637.5. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: Acetonitrile: Slightly soluble, DMSO: Soluble, Water: Slightly soluble. SMILES: CS(C1=CC=CC(C[C@@H](C([O-])=O)NC(C2=C(Cl)C=C(CN(C(C3=CC(OC=C4)=C4C=C3)=O)CC5)C5=C2Cl)=O)=C1)(=O)=O.[Na+]. InChi Code: InChI=1S/C29H24Cl2N2O7S.Na/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18,/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37),/q,+1/p-1/t23-,/m0./s1. InChi Key: BPWOKOSRORLLIN-BQAIUKQQSA-M.